Jessica E. Bohonowych

Jessica E. Bohonowych

Auto-generated profile, based on publicly available information

Jessica E. Bohonowych

Foundation for Prader‐Willi Research Covina California USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Journal of Applied Research in Intellectual Disabilities
Verified
Journal Article
Open access
LSLauren Schwartz
Lauren Schwartz
CVCaroline Vrana-Diaz
Caroline Vrana-Diaz
JBJessica E. Bohonowych
Jessica E. Bohonowych
Lisa MatesevacLisa Matesevac
Lisa Matesevac
TSTheresa Strong
Theresa Strong
Background: Prader–Willi syndrome (PWS) is a rare neurodevelopmental disorder with symptoms that impact health and quality of life (QOL). There is limited data on global health, QOL and the relationship with mood in individuals with PWS. Methods: Parents completed three validated assessments, the Glasgow Depression Scale‐Carer Supplement (GDS‐CS), PROMIS Parent‐Proxy Global Health 7 and PROMIS Parent‐Proxy Life Satisfaction 8b, for 527 individuals with PWS. Results: Mean GDS‐CS score was 8.29 (SD 4.55), and 18% had a score of 13+, reflective of possible depression. Mean PROMIS Global Health and Life Satisfaction scores were 41.46 (SD 8.48) and 43.39 (SD 8.48), respectively, and are lower compared to the general population. Both PROMIS scales worsened with age, and scores on the PROMIS and GDS‐CS were associated with parent reports of depression for the person with PWS. Conclusions: These validated instruments may be useful for assessing mood and QOL in PWS.

11 August 2025 in Genetics in Medicine Open
Verified
Journal Article
Open access
CVCaroline Vrana-Diaz
Caroline Vrana-Diaz
JBJessica Bohonowych
Jessica Bohonowych
JRJaimie L. Richards
Jaimie L. Richards
BWBrandon M. Wilk
Brandon M. Wilk
MGManavalan Gajapathy
Manavalan Gajapathy
TSTheresa Strong
Theresa Strong
Prader-Willi syndrome (PWS) is a complex neurodevelopmental genetic disorder affecting multiple systems. We describe the design and feasibility of a fully remote, patient group-led, genome sequencing (GS) study that will evaluate the impact of genetic variants on the frequency and severity of PWS clinical symptoms, with responsible return of results. A total of 50 participants, or their legally authorized representative, provided consent via videoconference discussion and selected which genetic results would be returned. Participants were sent dried blood spot cards for GS and a buccal swab kit for orthogonal pharmacogenomics analysis. A subset of legally authorized representative LARs participated in semistructured interviews about their GS experience. All 50 participants completed the study and elected to receive their primary findings, and 48 of 49 participants who consented to receive pharmacogenomic information returned the buccal swab kit. Forty-seven participants consented to receive secondary findings per current American College of Medical Genetics guidelines; 2 had actionable results, with online genetic counseling support provided. Three families received medically significant findings related to variants associated with blood clot formation, which is important because individuals with PWS are at an increased risk for thrombotic events. Interview participants expressed a high degree of interest in the findings and emphasized the ease of participating in the study but felt the process was lengthy. A fully remote GS study is feasible to perform within a rare disease population, and responsibly returning genetic findings that are important to families is achievable.

7 November 2026 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
DEDavid Evans
David Evans
JBJessica E. Bohonowych
Jessica E. Bohonowych
LSLauren Schwartz
Lauren Schwartz
TSTheresa Strong
Theresa Strong

9 November 2026 in Research Square
Verified
Preprint
Open access
PDF file
EWElizabeth Worthey
Elizabeth Worthey
MGManavalan Gajapathy
Manavalan Gajapathy
BWBrandon Wilk
Brandon Wilk
DBDonna Brown
Donna Brown
CVCaroline Vrana-Diaz
Caroline Vrana-Diaz
TSTheresa Strong
Theresa Strong
Prader-Willi syndrome (PWS) results from loss of paternal gene expression at chromosome 15q11.2-q13. Conventional testing reliably establishes the diagnosis and defines the molecular class but may not resolve complex chromosome 15 architecture or detect genome-wide variation relevant to medication response and other clinical risks. Historical results generally remain the basis for lifelong classification without re-evaluation as technologies advance. We evaluated whether genome sequencing (GS) could add clinically useful information beyond molecular confirmation of PWS. Fifty individuals underwent GS through a fully remote, registry-enabled study integrating structural, copy-number, small-variant, pharmacogenomic, phenotype, and medication-history analyses with multidisciplinary interpretation, genetic counseling, and return of selected findings. Overall, 34/50 participants (68%) had at least one finding beyond that provided by conventional PWS testing. GS revealed previously unresolved or more complex chromosome 15 architecture in 13/50 participants (26%), refined or resolved molecular subtype assignments in 8/50 (16%), identified guideline-supported pharmacogenomic recommendations in 20/48 (41.7%), detected ACMG secondary findings in 2/47 (4.3%), and identified additional variants for clinically contextualized return in 12/47 (25.5%); categories were not mutually exclusive. In the largest GS PWS cohort reported to date, GS improved resolution of the disease-causing locus while identifying additional findings relevant to prescribing, surveillance, and individualized clinical evaluation. These results support genomic reassessment as a means of refining longstanding molecular classifications and identifying clinically relevant variation beyond the primary diagnosis, whilst demonstrating the feasibility of comprehensive genomic interpretation and responsible return of results through a fully remote framework.